

Kirk Andriano, PhD, Advisory Board Member:

Dr. Andriano brings 30 years of experience in research, development, and commercialization of absorbable materials for implantable devices, drug delivery systems and regenerative medicine to the team. In addition to his role as an Advisory Board Member for BBS - Bioactive Bone Substitutes, Oy, where he assisted in their 2018 Nordic Nasdaq IPO. He was Executive Director of R&D as Medicus Bioscience LLC, a drug delivery company. He was at various times, CEO, VP of R&D, and Board Member of Elute, Inc., a company focused on orthopedic combination products. He was also VP of R&D at Histogenics. Inc., a cell-based cartilage regeneration company, where he participated in the 2012 VC funding of \$49M for their Phase III Clinical Trial, and was CTO of ProChon Bio-Tech, Ltd., where he participated in the 2011 merger of ProChon with Histogenics. He out-licensed from Inion, Oy, IP that set up Curative Biosciences where he was CSO tasked to create an orthopaedic combination product company. Dr. Andriano was responsible for the executive management of Research & Development at Inion. While at Inion, he played a participatory role in leading the company's \$75M IPO as the first Finnish company on the Main Board of the London Stock Exchange. He was responsible for overall research, development, intellectual property, product development, preclinical, clinical and regulatory approval of biodegradable polymer and bio-ceramic implants in five therapeutic areas, which included; CMF, dental, sports medicine, orthopedic trauma and spinal applications. Prior to Inion, he held a senior level management position at MacroMed, Inc., and scientist position Atrix Laboratories, Inc., which were both drug delivery companies.

Dr. Andriano received a B.S., double major, in Chemistry and Biology from Utah State University and he received a M.S. and Ph.D. in Bioengineering from the University of Utah (Departments of Anesthesiology and Orthopaedic Surgery, respectively). He has held post-doctoral research positions at the University of Utah School of Medicine and the Advanced Polymer Systems Research Institute. He was a National Institutes of Health research fellow and a visiting professor and research scholar at Kyoto University in Kyoto Japan.

Biomaterials, Orthopaedics, Drug Delivery, Regenerative Medicine